Oncolytic viruses against cancer, promising or delusion?

Letafati, Arash; Ardekani, Omid Salahi; Naderisemiromi, Mina; Fazeli, Mohammad Mehdi; Jemezghani, Nillofar Asadi; Yavarian, Jila

doi:10.1007/s12032-023-02106-6

Cited by 2 publications

(1 citation statement)

References 131 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A live attenuated vaccine designed to protect humans against measles has been shown to also have an oncolytic effect against various types of malignant neoplasms [71]. The preferred targets for virus cell entry are receptors CD46 and nectin-4 that are overexpressed on the surface of tumor cells, making the MV a possible weapon against tumors [72][73][74][75][76][77][78][79]. Numerous preclinical studies of MV (MV-CEA) with a soluble component of the human carcinoembryonic antigen (CEA), serving as a traceable marker peptide, have been shown to have significant antitumor effects against glioblastoma xenografts [80][81][82][83].…”

Section: Other Oncolytic Virusesmentioning

confidence: 99%

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

Ageenko,

Vasileva,

Richter

et al. 2024

IJMS

View full text Add to dashboard Cite

Glioblastoma is one of the most malignant and aggressive tumors of the central nervous system. Despite the standard therapy consisting of maximal surgical resection and chemo- and radiotherapy, the median survival of patients with this diagnosis is about 15 months. Oncolytic virus therapy is one of the promising areas for the treatment of malignant neoplasms. In this review, we have focused on emphasizing recent achievements in virotherapy, both as a monotherapy and in combination with other therapeutic schemes to improve survival rate and quality of life among patients with glioblastoma.

show abstract

Section: Other Oncolytic Virusesmentioning

confidence: 99%

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

Ageenko,

Vasileva,

Richter

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Head and neck cancer: pathogenesis and targeted therapy

Liu,

Zhang,

Wen

et al. 2024

MedComm

View full text Add to dashboard Cite

Head and neck cancer (HNC) is a highly aggressive type of tumor characterized by delayed diagnosis, recurrence, metastasis, relapse, and drug resistance. The occurrence of HNC were associated with smoking, alcohol abuse (or both), human papillomavirus infection, and complex genetic and epigenetic predisposition. Currently, surgery and radiotherapy are the standard treatments for most patients with early‐stage HNC. For recurrent or metastatic (R/M) HNC, the first‐line treatment is platinum‐based chemotherapy combined with the antiepidermal growth factor receptor drug cetuximab, when resurgery and radiation therapy are not an option. However, curing HNC remains challenging, especially in cases with metastasis. In this review, we summarize the pathogenesis of HNC, including genetic and epigenetic changes, abnormal signaling pathways, and immune regulation mechanisms, along with all potential therapeutic strategies such as molecular targeted therapy, immunotherapy, gene therapy, epigenetic modifications, and combination therapies. Recent preclinical and clinical studies that may offer therapeutic strategies for future research on HNC are also discussed. Additionally, new targets and treatment methods, including antibody–drug conjugates, photodynamic therapy, radionuclide therapy, and mRNA vaccines, have shown promising results in clinical trials, offering new prospects for the treatment of HNC.

show abstract

Oncolytic viruses against cancer, promising or delusion?

Cited by 2 publications

References 131 publications

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

Combination of Oncolytic Virotherapy with Different Antitumor Approaches against Glioblastoma

Head and neck cancer: pathogenesis and targeted therapy

Contact Info

Product

Resources

About